Presbyopia - Epidemiology Forecast – 2030

Presbyopia - Epidemiology Forecast – 2030

  • January 2021 •
  • 50 pages •
  • Report ID: 6025292 •
  • Format: PDF
‘Presbyopia - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Presbyopia epidemiology in the United States.
Presbyopia Understanding
Presbyopia, a natural age-related condition, is the result of a gradual decrease in accommodative amplitude, from about 15 diopters (D) in early childhood to 1 D before the age of 60 years. An irreversible, normal physiologic condition that affects all primates, it impairs the ability to see clearly at near. It is a natural part of aging. Presbyopia usually becomes noticeable in the early to mid-40s and continues to worsen until around age 65.
Presbyopia is partly due to age-related changes in the proteins within the lens of the eye that cause it to become thicker, harder, and less flexible. This loss of flexibility affects the lens’s ability to refract light rays which, in turn, affects the eye’s capacity to focus. Age-related changes also occur in the muscle fibers surrounding the lens that aid in focus, further aggravating the problem.
Initial symptoms may be difficulties with prolonged close-up work, with tiring (eye strain) of the eyes; this may be worse in dim light. People may also notice difficulty in adjusting vision if they glance from a near object to a faraway one. This may progress to blurred vision when looking at objects close up and to headaches and eye strain when attempting close work.

Presbyopia Diagnosis
Presbyopia can be diagnosed by an optometrist, ophthalmologist, or physician, who takes a complete medical history to determine the extent of the vision problem. The doctor also tests the vision by having the patient read the text at a typically comfortable distance. If the diagnoses of presbyopia are confirmed, the doctor may perform a test to determine the extent of the focusing problem and the appropriate lens prescription. In this test, the doctor asks the patient to look through corrective lenses and continues to increase the magnification power until the words on the page are clear and comfortable enough to be read by the patient. A thorough assessment of the health of the eyes and associated structures is an integral component of the comprehensive adult eye and vision examination. This examination can lead to the diagnosis of systemic diseases and disorders that have ocular manifestations.

Epidemiology Perspective
The Presbyopia epidemiology division provides insights about the historical and current Presbyopia patient pool and forecasted trends for the United States. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
In 2020, the total prevalent cases in the United States were 117,995,432 cases. These cases are expected to grow with a significant CAGR in the study period 2018–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Presbyopia epidemiology [segmented as Total Prevalent Cases of Presbyopia, Total Diagnosed Cases of Presbyopia, Gender-specific Cases of Presbyopia, Age-specific Cases of Presbyopia, Severity-specific Cases of Presbyopia, and Treated cases of Presbyopia] in the United States, from 2018 to 2030.

The United States Presbyopia Epidemiology
• The United States, in 2020, accounted for 101,657,603 diagnosed cases. These cases are expected to grow with a significant CAGR in the study period 2018–2030.
• In the United States, the total gender-specific diagnosed cases of presbyopia were 40,663,041 for males and 60,994,562 for females in the year 2020.
• Based on secondary findings, presbyopia is more prevalent in females as compared to males.

Scope of the Report
• The Presbyopia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The Presbyopia Report and Model provide an overview of the risk factors and trends of Presbyopia in the United States.
• The report provides insight about the historical and forecasted patient pool of Presbyopia in the United States.
• The report helps to recognize the growth opportunities in the United States concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Presbyopia.
• The report provides the segmentation of the Presbyopia epidemiology by total prevalent cases in the United States.
• The report provides the segmentation of the Presbyopia epidemiology by total diagnosed cases in the United States.
• The report provides the segmentation of the Presbyopia epidemiology by gender-specific diagnosed cases in the United States.
• The report provides the segmentation of the Presbyopia epidemiology by age-specific diagnosed cases in the United States.
• The report provides the segmentation of the Presbyopia epidemiology by severity-specific diagnosed cases in the United States.
• The report provides the segmentation of the Presbyopia epidemiology by treated cases in the United States.

Report Highlights

• 10-Year Forecast of Presbyopia epidemiology
• The United States Coverage
• Total Prevalent Cases of Presbyopia
• Total Diagnosed Cases of Presbyopia
• Gender-specific Diagnosed Cases of Presbyopia
• Age-specific Diagnosed Cases of Presbyopia
• Severity-specific Diagnosed Cases of Presbyopia
• Treated Cases of Presbyopia
KOL-Views
We interview KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the United States concerning the patient population of Presbyopia?
• What are the key findings of the Presbyopia epidemiology in the United States during the study period (2018–2030)?
• What would be the total number of patients of Presbyopia in the United States during the study period (2018–2030)?
• At what CAGR the patient population is expected to grow in the United States during the study period (2018–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Presbyopia?

Reasons to buy
The Presbyopia Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the United States Presbyopia market.
• Quantify patient populations in the United States Presbyopia market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Presbyopia therapeutics in each of the markets covered.
• Understand the magnitude of the Presbyopia population by its severity.
• The Presbyopia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Presbyopia Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
Study Period: 2018–2030
• In the United States, the age-specific diagnosed cases of presbyopia were 28,902,652, 33,239,895, 24,048,630, and 15,466,425 cases for the age group less than 60 years, 60–69 years, 70–79 years, and ?80 years, in 2020.
• In the United States, 20,331,521 mild and 81,326,082 moderate to severe presbyopia cases were observed in 2020.
• In the United States, the total treated cases of presbyopia were observed as 81,326,082 cases in 2020. These cases are expected to grow with a significant CAGR in the study period 2018–2030.